Press Release

March 30, 2009

READING, MA – InfoMedics, Inc., the patient feedback company, recently presented a poster detailing patients' experiences with desonide hydrogel for the treatment of mild to moderate atopic dermatitis (AD). Patient-reported impressions of treatment response were found to provide a valuable complement to objective clinical observations, assisting physicians in evaluating new therapies. Over 1,000 patients and 530 healthcare providers from across the United States participated in the survey.

Overall, patients in this program reported very favorable experiences after their treatment with desonide hydrogel, including up to 60 percent reductions in symptom severity. Patients were invited to participate in the survey, conducted online and via telephone, by their healthcare providers, 73 percent of whom were dermatologists. Individual patient responses from pre- and post-treatment surveys were summarized in one-page reports sent to the patient's prescribing physician.

The poster was prepared by InfoMedics' Senior Director of Analytic Services Donna Kerney, PhD, in conjunction with Rosanne Ford, BA and Vincent Gotz, MS Pharm, of SkinMedica, Inc. Kerney presented the poster at the 67th Annual Meeting of American Academy of Dermatology, March 6-10, 2009, in San Francisco, CA. The research was supported by funding from SkinMedica, Inc.

"Not only does real-time feedback from their own patients help physicians to more thoroughly evaluate new therapies, there are demonstrable benefits to patients as well," said Kerney. "Self-assessment programs allow patients an opportunity to become more involved in their care and may help in increasing medication adherence."

The majority (68 percent) of respondents reported having used at least one medication previously for their AD. Among those patients, satisfaction with desonide hydrogel was nearly 2X higher on average than satisfaction with previous medications. Satisfaction with the treatment for all respondents averaged 7.7 out of 9, with 9 being "very satisfied." The vast majority (89 percent) of patients reported that they intend to continue using desonide hydrogel to treat their AD, and 85 percent would recommend the treatment to others.

About InfoMedics
InfoMedics, Inc. is the only pharmaceutical services provider that delivers clear, actionable patient feedback to physicians; this feedback is designed to improve patient-physician communications while providing brand insight to pharmaceutical manufacturers. Patient feedback assists physicians at the point-of-care to optimize treatment outcomes and improve medication compliance. InfoMedics' programs facilitate the communication channel between physicians and patients around the prescribed pharmaceutical treatment, enhancing awareness and accelerating market share growth.

InfoMedics works with the world's top 15 pharmaceutical companies. The company's programs increase average brand prescribing by 40% and deliver an average ROI of 4:1.

For additional information contact:
Ariane Doud
Matter Communications
978-499-9250 x239
ariane@matternow.com

Amy Weickert
InfoMedics, Inc.
781-904-4512
aweickert@infomedics.com